Literature DB >> 33659265

The Clinical Characteristics of Patients With Nonneutropenic Invasive Pulmonary Aspergillosis.

Lulu Liu1, Yu Gu2, Yu Wang1, Kunlu Shen3, Xin Su1,2,3.   

Abstract

Objective: The goal of this study was to reveal the clinical manifestations of nonneutropenic invasive pulmonary aspergillosis (IPA), which are different from those of neutropenic patients.
Methods: The clinical data of patients with nonneutropenic IPA were collected at the Department of Respiratory and Critical Care Medicine, Jinling Hospital, from February 2009 to November 2019. We analyzed the general conditions, clinical manifestations, imaging findings, and laboratory tests of these IPA patients.
Results: A total of 116 patients with nonneutropenic IPA (31 proven and 85 probable) were included. They had an average age of 59.8 years. The most common underlying disease was chronic obstructive pulmonary disease (COPD, n = 33). The common clinical symptoms included cough (93.1%, n = 108), expectoration (59.5%, n = 69), fever (57.8%, n = 67), hemoptysis (30.2%, n = 35), and dyspnea (40.5%, n = 47). The common CT imaging manifestations included consolidation (47.4%, n = 55), cavities (47.4%, n = 55), air crescent sign (14.7%, n = 17), and nodules (8.6%, n = 10). Multiple lesions (74.1%, n = 86) were more common than single lesions (17.2%, n = 20) and diffuse lesions (8.6%, n = 10). The positive rate of laboratory tests was 88.2% (30/34) for BALF galactomannan (GM), 55.4% (56/101) for serum GM, 45.3% (48/106) for 1,3-β-D-glucan (BDG), 43.3% (46/106) for sputum culture, and 36.4% (20/55) for BALF culture. Patients who had high serum GM level [GM optical density index (ODI) >1] were more likely to have severe respiratory symptoms and higher serum ferritin. Further investigation showed that there was a positive correlation between serum GM level and serum ferritin level.
Conclusion: The clinical symptoms and radiological manifestations of nonneutropenic IPA are diverse and often lead to delayed diagnosis. It is important to become more vigilant of aspergillosis in nonneutropenic patients in order to achieve early diagnosis and treatment and to reduce mortality.
Copyright © 2021 Liu, Gu, Wang, Shen and Su.

Entities:  

Keywords:  clinical manifestation; invasive pulmonary aspergillosis; nonneutropenic; serum GM; serum ferritin

Year:  2021        PMID: 33659265      PMCID: PMC7917130          DOI: 10.3389/fmed.2021.631461

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  3 in total

1.  Two entities in pulmonary nodules of a diabetic patient receiving corticosteroid therapy for bullous pemphigoid: an autopsy case report.

Authors:  Reimi Mizushima; Kotaro Haruhara; Nei Fukasawa; Mari Satake; Akira Fukui; Kentaro Koike; Nobuo Tsuboi; Hiroyuki Takahashi; Takashi Yokoo
Journal:  BMC Infect Dis       Date:  2022-07-07       Impact factor: 3.667

2.  A case of non-neutropenic invasive pulmonary aspergillosis under immune checkpoint inhibitor therapy for malignant melanoma.

Authors:  Yoshinori Uchida; So Shimamura; Shuichiro Ide; Kazuki Masuda; Masafumi Saiki; Yusuke Sogami; Hiroshi Ishihara
Journal:  Respir Med Case Rep       Date:  2022-03-11

3.  Clinical and Epidemiological Profile of Patients with Invasive Aspergillosis from a Fourth Level Hospital in Bogota, Colombia: A Retrospective Study.

Authors:  Ana Goyeneche-García; Juan Rodríguez-Oyuela; Guillermo Sánchez; Carolina Firacative
Journal:  J Fungi (Basel)       Date:  2021-12-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.